Equillium stock rallies 26% on itolizumab study data

Shares of Equillium (NASDAQ:EQ) soared 26% Thursday after the company and partner Biocon reported positive topline results from a Phase 2 study of the drug itolizumab in the treatment of moderate to severe ulcerative colitis.

Itolizumab demonstrated clinical efficacy after